Yehenew M. Agazie
Affiliations: | School of Medicine | West Virginia University, Morgantown, WV, United States |
Area:
Biochemistry, Cell Biology, OncologyWebsite:
https://directory.hsc.wvu.edu/Profile/28124Google:
"Yehenew Mekonnen Agazie"Mean distance: (not calculated yet)
Parents
Sign in to add mentor| Jeremy S. Lee | grad student | 1995 | University of Saskatchewan | |
| (Triplex DNA in the eukaryotic chromosome.) | ||||
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Lade DM, Agazie YM. (2023) Targeting SHP2 with an Active Site Inhibitor Blocks Signaling and Breast Cancer Cell Phenotypes. Acs Bio & Med Chem Au. 3: 418-428 |
| Lade DM, Nicoletti R, Mersch J, et al. (2022) Design and synthesis of improved active-site SHP2 inhibitors with anti-breast cancer cell effects. European Journal of Medicinal Chemistry. 247: 115017 |
| Martin E, Agazie YM. (2021) SHP2 potentiates the oncogenic activity of beta-catenin to promote triple-negative breast cancer. Molecular Cancer Research : McR |
| Hartman Z, Geldenhuys WJ, Agazie YM. (2020) Novel Small-Molecule Inhibitor for the Oncogenic Tyrosine Phosphatase SHP2 with Anti-Breast Cancer Cell Effects. Acs Omega. 5: 25113-25124 |
| Hartman Z, Geldenhuys WJ, Agazie YM. (2020) A specific amino acid context in EGFR and HER2 phosphorylation sites enables selective binding to the active site of Src homology phosphatase 2 (SHP2). The Journal of Biological Chemistry |
| Agazie Y, Hartman Z. (2020) Abstract P3-10-20: Targeting the tyrosine phosphatase SHP2 is efficacious against HER2-positive breast cancer Cancer Research. 80 |
| Agazie Y, Hartman Z. (2019) Abstract P6-20-17: Targeting SHP2 for the treatment of HER2-positive breast cancer Cancer Research. 79 |
| Zhao H, Martin E, Matalkah F, et al. (2018) Conditional knockout of SHP2 in ErbB2 transgenic mice or inhibition in HER2-amplified breast cancer cell lines blocks oncogene expression and tumorigenesis. Oncogene |
| Matalkah F, Martin E, Zhao H, et al. (2016) SHP2 acts both upstream and downstream of multiple receptor tyrosine kinases to promote basal-like and triple-negative breast cancer. Breast Cancer Research : Bcr. 18: 2 |
| Zhao H, Agazie YM. (2015) Inhibition of SHP2 in basal-like and triple-negative breast cells induces basal-to-luminal transition, hormone dependency, and sensitivity to anti-hormone treatment. Bmc Cancer. 15: 109 |